Application of a drug in the preparation of a drug for reducing statin muscle toxicity

A technology of myotoxicity and drugs, which is applied in the application field of drugs in the preparation of drugs to reduce the myotoxicity of statins, can solve the problems of undisclosed application of statins to myotoxicity, and achieve the purpose of promoting sports rehabilitation, improving the mechanism of action, increasing The effect of exercise tolerance

Active Publication Date: 2022-07-19
SHANGHAI PHARMA GRP QINGDAO GROWFUL PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above-mentioned patent does not disclose the application of the drug in reducing the myotoxicity of statins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a drug in the preparation of a drug for reducing statin muscle toxicity
  • Application of a drug in the preparation of a drug for reducing statin muscle toxicity
  • Application of a drug in the preparation of a drug for reducing statin muscle toxicity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The drug tablet for reducing the muscle toxicity of statins is made from the following raw materials by weight:

[0055]

[0056] The preparation method of the pharmaceutical tablet comprises the following steps: taking ginseng, Coptis chinensis, Vinegar Corydalis, Hawthorn and half of Astragalus in the crude drug, pulverizing it into fine powder, adding the remaining eight-flavor crude drug and the remaining Astragalus and decocting twice with water , 2 hours for the first time, 1.5 hours for the second time, combined decoction, filtered, the relative density of the filtrate was 1.06 to 1.12 when the filtrate was concentrated to 90 ° C, allowed to cool, doubled the amount of ethanol to precipitate, took the supernatant, recovered Ethanol, and concentrated to a clear paste with a relative density of 1.20 to 1.22 at 90 ° C, mixed with the above-mentioned medicinal powder, made into granules, dried, compressed into 1000 tablets (small tablets), sugar-coated or film-coat...

Embodiment 2

[0059] The medicinal capsule for reducing the muscle toxicity of statins is made from the following raw materials by weight:

[0060]

[0061]

[0062] The preparation method of the pharmaceutical capsules comprises the following steps: taking ginseng, Coptis chinensis, vinegar Corydalis, hawthorn and half of the astragalus in the raw material medicine, crushing them into fine powder, adding the remaining eight medicinal materials and the remaining astragalus root and decocting twice with water , 2 hours for the first time, 1.5 hours for the second time, combined decoction, filtered, the relative density of the filtrate was 1.06 to 1.12 when the filtrate was concentrated to 90 ° C, allowed to cool, doubled the amount of ethanol to precipitate, took the supernatant, recovered ethanol, and concentrated to a clear paste with a relative density of 1.20-1.22 at 90°C, mixed with the above-mentioned medicinal powder to prepare capsules.

[0063] For the preparation of a medicin...

Embodiment 3

[0065] The drug granules for reducing the muscle toxicity of statins are made from the following raw materials by weight:

[0066]

[0067] The preparation method of the medicinal granules comprises the following steps: taking ginseng, Coptis chinensis, Vinegar Corydalis, hawthorn and half of Astragalus in the crude drug, pulverizing them into fine powder, and boiling the remaining eight-flavor crude drugs and remaining Astragalus twice with water , 2 hours for the first time, 1.5 hours for the second time, combined decoction, filtered, the relative density of the filtrate was 1.06 to 1.12 when the filtrate was concentrated to 90 ° C, allowed to cool, doubled the amount of ethanol to precipitate, took the supernatant, recovered ethanol, and concentrated to a clear paste with a relative density of 1.20-1.22 at 90°C, mixed with the above-mentioned medicinal powder to prepare granules.

[0068] For preparing a medicine for reducing the muscle toxicity of a statin, the statin i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the use of a medicine in preparing a medicine for reducing the muscle toxicity of statins. The experimental results show that Yangxinshi Tablets can enhance mitochondrial activity, improve oxidative stress and inhibit ApoE induced by high-fat feeding during exercise training. ‑ / ‑ Myolysis in mice, reducing statin-related skeletal muscle damage, and improving exercise capacity have significant effects.

Description

technical field [0001] The invention relates to a new use of a medicine, in particular, the invention relates to the application of a medicine in the preparation of a medicine for reducing the muscle toxicity of statins, and belongs to the application field of traditional Chinese medicine. Background technique [0002] 3-Hydroxy-3-methylglutathione coenzyme A (HMG-CoA) reductase inhibitors (statins) are commonly used drugs for the treatment and prevention of cardiovascular disease. Statin intolerance refers to the inability to tolerate doses of statins sufficient to reduce cardiovascular risk, which may be caused by statin-related side effects. The main side effect of statins is muscle-related myopathy, usually defined as muscle pain, tenderness, or weakness, accompanied by a substantial increase in blood creatine kinase concentrations. Myopathy caused by statins ranges from 1-5% to 15-20% of clinical trials and can be fatal in severe cases. In other cases (eg, in combinat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/804A61P21/00A61P9/00A61K31/366
CPCA61K36/481A61K36/344A61K36/537A61K36/488A61K36/296A61K36/734A61K36/804A61K36/232A61K36/718A61K36/66A61K36/074A61K36/258A61K36/484A61P21/00A61P9/00A61K31/366A61K2300/00
Inventor 沈晓燕叶冠吴若铭洪毅高莉
Owner SHANGHAI PHARMA GRP QINGDAO GROWFUL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap